Prior authorization required when selection criteria are met

Obtain prior authorization for the listed CPT/HCPCS codes when the policy selection criteria are met; authorization is required when submitting claims for covered facial surgery and diagnostic testing codes noted as covered only if selection criteria apply.

• Covered codes include 15756, 15758, 15840-15845, 20920-20922, 61590, 64716, 64742, 64864-64868, 64885-64886, 69740-69745, 67912, 95933 (see policy CPT/HCPCS list).
• Prior authorization is expected when selection criteria for surgical or diagnostic services are applicable per Aetna processes.

Prior authorization: document failed spontaneous recovery and objective findings

For reconstructive or reanimation procedures, prior authorization should document failure of expected spontaneous recovery and provide objective electrophysiologic evidence and a proposed surgical plan.

• Document lack of return of function after an observation period (commonly ~12 months) or objective evidence of no reinnervation (EMG/ENoG).
• Include the proposed reconstructive procedure and planned staging (e.g., CFNG followed by FFMT).

Prior authorization recommended for complex reconstruction

Prior authorization is recommended for complex reconstructive procedures and should include paralysis chronicity, prior conservative therapy, and the detailed surgical plan because these techniques are often staged and microvascular.

• Examples include free functional muscle transfer, cross-face nerve grafting, and temporalis transfer.
• Provide rationale for staging (e.g., CFNG then FFMT) or single-stage alternatives (e.g., masseteric nerve transfer).

Prior authorization: capture severity evidence and timing for decompression

When requesting authorization for facial nerve decompression, include severity evidence and timing rationale such as complete paralysis, >90% degeneration on ENoG, absent voluntary EMG, and the timing since onset to support the surgical approach.

• ENoG showing >90% degeneration and absent voluntary EMG (within ~14 days) are cited candidate criteria.
• Document timing since symptom onset and rationale if decompression is being considered beyond typical early windows (references discuss ≤14 days vs up to 90 days in select cases).

Prior authorization: confirm prior conservative therapies before selective neurectomy/myectomy

Prior authorization for selective neurectomy or myectomy should verify that conservative first- and second-line therapies were attempted and documented before approving surgery.

• Document trials of chemo-denervation (Botox) and neuromuscular retraining and their outcomes.
• Authorization decisions should reflect individualized consideration given limited long‑term evidence.

No other prior authorization rules specified in this excerpt

This excerpt does not specify additional prior authorization rules beyond those described elsewhere in the policy.

• Background sections and some supplemental chunks provide evidence reviews but do not add new prior authorization requirements.

Supplemental information: no prior authorization specified

No prior authorization requirements are specified in the supplemental information section of the policy.

• The Additional Information section lists external resources and does not state authorization requirements.

No explicit step therapy sequence specified

The policy does not define an explicit step therapy sequence for Bell's palsy treatments.

• Treatment recommendations and evidence summaries are provided, but no mandated stepwise medication or procedure sequence is specified.

Conservative/physical therapies preferred as initial approach

Conservative and physical therapies (tailored facial exercises, neuromuscular retraining) are supported by low-quality evidence and are reasonable initial management prior to considering invasive procedures.

• Physical therapy evidence is mixed; tailored facial exercises may help selected patients, particularly chronic or moderate paralysis.
• These approaches are generally preferred initial options before surgical reconstruction when feasible.

Document staged vs single-stage reconstruction considerations

Document rationale when choosing staged versus single-stage reconstruction; staged approaches (e.g., CFNG then FFMT) are described as a common strategy while single-stage masseteric nerve transfers are an alternative in selected patients.

• Staged CFNG with FFMT may restore spontaneous mimetic function; masseteric or temporalis transfers may be chosen for single-stage reconstruction or limited life expectancy.

Document prior non-surgical therapies and outcomes before invasive procedures

Before elective invasive procedures, document prior non-surgical therapies and their outcomes so that authorization and clinical decisions can confirm appropriate stepwise management.

• Include facial retraining, physical therapy, PNF, and botulinum toxin treatments and the clinical response.
• Objective functional measures and symptom duration should be recorded.

Synkinesis: chemo-denervation and retraining first; surgery third-line

For management of synkinesis, initial treatment typically uses chemo-denervation (Botox) and neuromuscular re-training; surgery (selective myectomy/neurectomy) is considered a later, third-line option.

• Clinical practice recommendations designate surgery as third-line and stress individualized decision-making after discussing complications and limited success rates.
• Document prior Botox use and retraining attempts when seeking authorization for surgical synkinesis interventions.

Surgical coverage: document duration >12 months, functional deficit, and electrophysiology

Documentation supporting surgical coverage must show paralysis duration greater than 12 months, an impaired functional deficit (mastication, speech, or vision), and electrophysiologic testing indicating low likelihood of spontaneous recovery.

• Electromyography or electroneuronography findings demonstrating no reasonable likelihood of recovery are required.
• These elements are necessary for facial surgery to be considered medically necessary.

Surgical planning: include duration, EMG/ENoG, prior therapy, and technique rationale

For surgical planning and authorization, include duration of paralysis, prior EMG/ENoG results, prior conservative management, and the rationale for the chosen reconstructive technique.

• Specify timing since onset because timing and etiology influence choice and expected outcomes.
• Describe planned staging (e.g., nerve grafting then muscle transfer) and expected goals (spontaneous mimetic function vs voluntary movement).

Required clinical rationale: etiology, duration, prior treatments, and method justification

Clinical rationale submitted for authorization should state etiology, duration of paralysis, prior treatments, and why the chosen reconstruction method is appropriate (e.g., direct repair, CFNG+FFMT, temporalis transfer).

• Clarify whether the surgical goal is restoration of spontaneous mimetic function or provision of voluntary movement.
• Relate the chosen method to patient factors such as age, comorbidity, and soft tissue deficits.

Preoperative documentation: ENoG/EMG, imaging, HB grade, and timing rationale

Preoperative documentation should include ENoG, EMG, imaging, and House‑Brackmann grading, with timing from symptom onset and the rationale for the selected surgical approach (e.g., middle cranial fossa vs trans‑mastoid).

• Record electrophysiologic results (e.g., >90% degeneration on ENoG where applicable) and absent voluntary EMG when relevant to decompression candidacy.
• Document days since onset to support timing-based decisions.

Document prior synkinesis treatments (Botox, retraining) and outcomes

When documenting prior synkinesis treatments for authorization, include details of prior Botox/chemo‑denervation, neuromuscular retraining, the types used, duration, and clinical response.

• Note objective pre- and post-treatment assessments and any need for repeat injections.
• For surgical synkinesis requests, demonstrate failure or inadequate response to first- and second-line therapies.

Telerehabilitation: recommend detailed intervention and AE reporting

Although no mandatory telerehabilitation documentation is specified, the policy recommends detailed reporting of telerehabilitation interventions and adverse events using standardized reporting frameworks.

• Use TIDieR-style detail for interventions and record adverse event characteristics to support safety and outcomes reporting.
• Maintain session documentation and AE logs even though not currently prescriptive for authorization.

Supplemental resources: reference links for providers

The Additional Information section provides links to Aetna resources (glossary, app, legal notices) that providers may reference but does not impose specific documentation or authorization requirements.

• Providers may consult listed resources for administrative and general guidance; these links do not change clinical documentation expectations.

Denial risk: experimental, investigational, or unproven procedures

Claims for procedures listed as experimental, investigational, or unproven (such as acupuncture, antivirals, botulinum toxin, electrical stimulation, facial nerve decompression, facial retraining therapy, PRP, neuromuscular ultrasound, telerehabilitation, TMS, Vitamin B‑12) may be denied because effectiveness has not been established.

• The policy explicitly labels numerous diagnostics and treatments as experimental/investigational/unproven and at risk for denial.
• Review the policy's experimental/unproven list before submitting claims for these services.

Denial risk: limited randomized evidence for surgical interventions

Surgical interventions for Bell's palsy are supported by very low‑quality randomized evidence and trials have not demonstrated clear benefit; lack of demonstrated benefit may lead to denial when surgery is requested solely for Bell's palsy without specific indications.

• Cochrane and systematic review data cite very low‑quality RCT evidence insufficient to conclude benefit of surgical intervention for routine Bell's palsy management.
• Authorization should be supported by documented indications and failed conservative management where appropriate.

Caution: limitations of procedures using non‑facial motor nerves

Procedures that rely on motor nerves other than the facial nerve (e.g., temporalis transposition, hypoglossal or spinal accessory neurotization) have limitations and do not restore a truly spontaneous smile; these limitations should be acknowledged in planning and documentation.

• Neurotization by the contralateral facial nerve is associated with recovery of spontaneous smile more often than transfers using non‑facial motor nerves.
• Document expected functional outcomes and patient counseling when non‑facial nerve neurotization is proposed.

Preoperative counseling: document discussion of hearing loss risk before decompression

Prior to facial nerve decompression, discuss and document the risk of postoperative hearing loss (reported ~2–5%) and perform appropriate preoperative assessments; absence of documented counseling or assessments may affect coverage decisions.

• Counsel patients on risks (including possible hearing loss) and record this discussion in the medical record.
• Include hearing assessment data where available when seeking authorization for decompression.

Selective myectomy/neurectomy: third‑line caution and documentation requirement

Selective myectomy or neurectomy should be considered a third‑line, individualized option and is recommended only after failed conservative management; inadequate prior management or lack of individualized risk discussion could lead to denial.

• Ensure prior Botox and neuromuscular retraining are documented and that the informed consent discussion addresses limited long‑term evidence and potential complications.
• Authorization reviewers will expect demonstration of prior conservative trials.

Background sections: no explicit authorization rules

Several background and evidence review sections do not add explicit authorization rules; they provide context and references for clinical decision‑making but are not prescriptive for prior authorization.

• Use these sections for clinical context; rely on the policy's prior_auth and documentation sections for authorization requirements.

Additional information: no authorization triggers specified

Supplemental information in the Additional Information section does not state authorization or clinical denial triggers; it lists general resources and links only.

• Providers should not infer authorization rules from these supplemental links; follow the policy's coverage and prior authorization guidance.